- Home
- NUVL vs JXN Comparison
NUVL vs JXN Comparison
Compare NUVL & JXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- JXN
- Stock Information
- Founded
- NUVL 2017
- JXN 1961
- Country
- NUVL United States
- JXN United States
- Employees
- NUVL N/A
- JXN N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- JXN Life Insurance
- Sector
- NUVL Health Care
- JXN Finance
- Exchange
- NUVL Nasdaq
- JXN Nasdaq
- Market Cap
- NUVL 5.4B
- JXN 6.0B
- IPO Year
- NUVL 2021
- JXN N/A
- Fundamental
- Price
- NUVL $80.48
- JXN $88.96
- Analyst Decision
- NUVL Strong Buy
- JXN Hold
- Analyst Count
- NUVL 10
- JXN 5
- Target Price
- NUVL $119.60
- JXN $94.80
- AVG Volume (30 Days)
- NUVL 582.7K
- JXN 694.9K
- Earning Date
- NUVL 08-07-2025
- JXN 08-06-2025
- Dividend Yield
- NUVL N/A
- JXN 3.60%
- EPS Growth
- NUVL N/A
- JXN N/A
- EPS
- NUVL N/A
- JXN 1.09
- Revenue
- NUVL N/A
- JXN $7,422,000,000.00
- Revenue This Year
- NUVL N/A
- JXN $114.12
- Revenue Next Year
- NUVL N/A
- JXN $2.02
- P/E Ratio
- NUVL N/A
- JXN $81.33
- Revenue Growth
- NUVL N/A
- JXN 110.55
- 52 Week Low
- NUVL $55.54
- JXN $64.70
- 52 Week High
- NUVL $113.51
- JXN $115.22
- Technical
- Relative Strength Index (RSI)
- NUVL 59.85
- JXN 61.80
- Support Level
- NUVL $76.27
- JXN $87.62
- Resistance Level
- NUVL $80.90
- JXN $90.20
- Average True Range (ATR)
- NUVL 2.55
- JXN 2.12
- MACD
- NUVL 0.19
- JXN 0.34
- Stochastic Oscillator
- NUVL 81.61
- JXN 86.80
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About JXN Jackson Financial Inc.
Jackson Financial Inc helps Americans grow and protect their retirement savings and income to enable them to pursue financial freedom for life. Its retail product offerings are comprised of annuities, designed to help retail investors save for and live in retirement. Its diverse suite of annuities includes a variable, fixed index, and fixed annuities. The company manages its business through three segments: Retail Annuities, Institutional Products, and Closed Life and Annuity Blocks and Corporate and Other segments. The company generates the majority of its revenue from the Retail Annuities segment, which offers a variety of retirement income and savings products of variable annuities, registered index-linked annuities ("RILA"), fixed index annuities, fixed annuities, and payout annuities.